Company intelligence / Profile preview

Guangzhou HuiBoRui Biological Pharmaceutical Technology Co., Ltd.

Guangzhou, Guangdong, Chinanature.com ↗

Ownership: Private
Development stage: Other

Overview

The company has a Phase 1 clinical trial for KDR2-2 eye drops that was recruiting 62 healthy volunteers to evaluate safety, tolerability, and pharmacokinetics as of November 2020[1].

Therapeutic areas: Ophthalmology
Modalities: Eye drops
Industry: Biotech

Beyond the preview

Go deeper on Guangzhou HuiBoRui Biological Pharmaceutical Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou HuiBoRui Biological Pharmaceutical Technology Co., Ltd..

Explore the full profile